Magnolia MedTech Fund Launches for Dutch University Spin-Outs

TL;DR
Thuja Capital is launching the Magnolia MedTech Fund, a new vehicle built to invest at the single hardest moment in medtech company-building: the point where university research has to become an actual, investable company. The fund sits inside a Dutch government-backed program called TTT MedTech 2026, and it brings together an unusually deep bench of partners, Dutch university medical centres and technical universities, health insurer VGZ, device manufacturer Nolato Unitron, and the Netherlands Enterprise Agency, all committing capital and hands-on expertise to the same vehicle. No fund size has been disclosed yet, which is normal at this stage of a program-anchored launch, but the partner list is the real story.
Key Takeaways
This fund exists because a policy gap got identified first. The Dutch MedTech Growth Plan, published in December 2025, found that most of the Netherlands' dedicated medtech funds have stopped operating in recent years, even as Europe overall captures just 5% of global venture capital against 52% for the United States. Magnolia is a direct response to that finding rather than an opportunistic fund launch chasing a hot sector.
It's targeting the single riskiest inflection point in medtech. Most early-stage capital shows up once a spin-out already has a company structure and a founding team in place. Magnolia is built to invest before that, at the moment university research first needs to become an investable entity, which is exactly the gap where Dutch medtech inventions have historically stalled.
The consortium model is the differentiator, not just the capital. Dutch UMCs and technical universities, a health insurer, a device manufacturer, and a government agency are all named partners, not passive LPs. The fund's own framing is that investors, management, and knowledge partners jointly commit to hands-on coaching, which is a meaningfully more hands-on structure than a typical seed fund's advisory-board arrangement.
Thuja brings two decades of medtech- and biotech-specific underwriting to the mandate. Founded in 2007, Thuja has spent its history investing at the lab-to-clinic boundary across both biotech and medtech, and its Managing Partner roster includes a former Head of European Investments at Philips Ventures. That's a firm whose existing muscle memory lines up unusually well with what Magnolia is trying to do.
Fund Overview
Fund Name: Magnolia MedTech Fund
Fund Size: Not disclosed
Stage: Pre-company formation and earliest-stage (university spin-out creation)
Check Size: Not disclosed
Geography: The Netherlands (spin-outs from Dutch universities and knowledge institutes)
Focus: Devices, enabling technology, and digital health solutions built on novel technology, or novel applications of existing technology, developed at a Dutch knowledge institute and addressing a clear unmet medical need
Key LPs/Partners: Dutch university medical centres and technical universities, health insurer VGZ, medical device manufacturer Nolato Unitron, Stichting Santiago, and the Netherlands Enterprise Agency (RVO), under the Ministry of Economic Affairs and Climate Policy
Why This Fund Matters
The lab-to-company transition is the single most under-capitalized stage in medtech, and it's under-capitalized for structural reasons that don't go away on their own. A piece of university research can be scientifically excellent and still have no obvious path to a company, because nobody has yet done the unglamorous work of figuring out a regulatory strategy, a reimbursement pathway, and a founding team to actually build the thing. Most venture capital, even most early-stage venture capital, shows up after that work is already done. Magnolia is explicitly built to fund the work of doing it.
The timing lines up with a real, documented problem rather than a marketing narrative. The Dutch MedTech Growth Plan's finding that most of the country's dedicated medtech funds have ceased operating is a genuinely striking data point for a country with the Netherlands' research base, and the 5%-versus-52% venture capital gap between Europe and the US is the kind of structural disadvantage that shows up repeatedly in European biotech and medtech policy discussions. Launching a fund specifically to plug the earliest part of that gap, backed by the government program designed to address it, is a sensible and well-targeted response.
What's genuinely distinctive here is the partner structure. VGZ's involvement as a health insurer, rather than just a financial LP, means the fund has a direct line into reimbursement and market-access thinking from day one, which is usually the single hardest thing for a first-time medtech founder to get right. Nolato Unitron's participation as a device manufacturer adds manufacturing and regulatory-pathway expertise that university spin-out teams almost never have in-house. Pairing those two alongside the UMCs and technical universities that actually produce the research gives Magnolia a genuinely integrated pipeline from lab bench to, eventually, patient use, rather than a fund that simply writes checks and hopes the rest sorts itself out.
The Team
Michel Briejer, Managing Partner at Thuja Capital, will lead Magnolia's management on behalf of the firm. Thuja's broader partner bench includes Evan Castiglia, who joined as Managing Partner in 2023 after serving as Partner and Head of European Investments at Philips Ventures, where he led venture investments in early and growth-stage healthcare companies, and before that as Chief Business Officer at the US life sciences company RareCyte. Thuja was founded in 2007 by Harrold van Barlingen and has invested across both biotech and medtech since. The firm's operating bench also includes Eline van Beest, who joined in 2019 as Operating Partner and founded NightBalance, a prior Thuja Fund I portfolio company later acquired by Philips, and Florian Ludwig, a Venture Partner who joined as Investment Director in 2016 and now leads CardiacBooster, a Fund II portfolio company, as CEO.
What This Means for Founders
If you're a researcher at a Dutch university or knowledge institute sitting on medtech intellectual property with no clear company structure yet, Magnolia is built specifically for you, arguably more so than any other active fund in the Netherlands right now. The fund's entire reason for existing is to fund the step most investors skip, so researchers who've been told their technology is "too early" by generalist health-tech funds are exactly the audience this is meant to serve.
The hands-on coaching commitment from investors, management, and knowledge partners is worth taking seriously rather than treating as boilerplate. With UMCs, a health insurer, and a device manufacturer all named as active partners, founders coming through this program should expect real operational support on regulatory strategy and market access, not just capital and a board seat.
Fund Momentum Take
Magnolia is one of the more structurally interesting fund launches we've covered this year, not because of the size, which hasn't been disclosed, but because of how deliberately it's been built to solve a specific, well-documented market failure rather than to chase a sector trend. A consortium of universities, a health insurer, and a device manufacturer all co-investing in the same early-stage vehicle is a genuinely unusual structure, and it's one that, if it works, other European governments facing the same medtech-funding gap will likely want to copy.
The obvious open item is fund size, and by extension how much actual capital this consortium is prepared to deploy against a stated ambition that spans the entire Dutch medtech research base. A fund built around the right structure can still be too small to matter if it only has the resources to back a handful of spin-outs a year. We'd want to see a disclosed target size, or at least a sense of how many spin-outs Magnolia expects to fund annually, before calling this a complete answer to the gap the MedTech Growth Plan identified.
Thuja's own track record, including a Fund I portfolio company acquired by Philips and a Fund II company now run by one of its own former investment directors, gives this launch more credibility than a brand-new manager would carry into the same structure. That's the kind of operator continuity that tends to matter most at exactly the stage Magnolia is targeting.
Frequently Asked Questions
What stage does the Magnolia MedTech Fund invest at?
The earliest possible stage: the transition from university research to an investable company, before a formal spin-out structure typically exists. This is earlier than most seed-stage medtech funds operate.
How large is the fund?
Not disclosed. Thuja Capital's official announcement and press release do not state a target or committed fund size.
Who manages Magnolia, and who are its partners?
Thuja Capital manages the fund, with Michel Briejer, the firm's Managing Partner, leading on Magnolia's behalf. Partners include Dutch university medical centres and technical universities, health insurer VGZ, medical device manufacturer Nolato Unitron, Stichting Santiago, and the Netherlands Enterprise Agency, coordinated by the University of Twente.
What is the TTT MedTech 2026 program?
Thematic Technology Transfer MedTech 2026 is a Dutch government initiative, made possible by the Ministry of Economic Affairs and Climate Policy, that pairs a consortium of knowledge partners with an investment fund to help translate scientific research into companies. Magnolia is the investment pillar of that program.
What geography and sectors does the fund cover?
Spin-outs from Dutch universities and knowledge institutes nationally, focused on devices, enabling technology, and digital health solutions built on novel technology, or novel applications of existing technology, that address a clear unmet medical need.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.
Related funds in the index
MedTech funds from the verified index
| Fund | Size | Stage | Location | Focus |
|---|---|---|---|---|
| Sofinnova Crossover Fund II | €725 million EUR | Series C | France | Biotech, MedTech +1 |
| Genesys University Seed Fund | C$30M CAD | Seed | Canada | Biotech, MedTech |
| Sofinnova MD Start Fund IV | €82M EUR | Seed | France | MedTech |
| GD1 Core Fund II | NZ$56.7M NZD | Pre Seed | New Zealand | EnergyTech, Space +6 |
| Cross Border Impact Ventures Fund II | $58M USD | Series A | Canada | Digital Health, MedTech +2 |